Jefferies analyst Amin Makarem reiterated a Buy rating and $56.00 price target on UroGen Pharma (NASDAQ: URGN)The analyst comments: “TYRA’s ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE